

evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 2, 1995.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *Crestar Financial Corporation*, Richmond, Virginia; to acquire TideMark Bancorp, Inc., Newport News, Virginia, and thereby indirectly acquire TideMark Bank, Newport News, Virginia, and engage in operating a savings and loan association, pursuant to § 225.25(b)(9) of the Board's Regulation Y. Crestar also has applied to acquire 19.9 percent of TideMark Bank, Newport News, Virginia.

Board of Governors of the Federal Reserve System, December 7, 1994.

William W. Wiles,

Secretary of the Board.

[FR Doc. 94-30550 Filed 12-12-94; 8:45 am]

BILLING CODE 6210-01-F

IBW, Inc., et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than January 6, 1995.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *IBW, Inc.*, Washington, D.C.; to become a bank holding company by acquiring 100 percent of the voting shares of Industrial Bank of Washington, Washington, D.C.

B. Federal Reserve Bank of Atlanta (Zane R. Kelley, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. *Regions Financial Corporation*, Birmingham, Alabama; to merge with First Commercial Bancshares, Inc., Chalmette, Louisiana, and thereby indirectly acquire First National Bank of St. Bernard Parish, Chalmette, Louisiana.

C. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *Boatmen's-Illinois, Inc.*, St. Louis, Missouri; to become a bank holding company by acquiring 100 percent of the voting shares of Boatmen's Bank of South Central Illinois, Mt. Vernon, Illinois.

2. *Boatmen's Bancshares, Inc.*, St. Louis, Missouri; to acquire 100 percent of the voting shares of Salem Community Bancorp, Inc., Salem, Illinois, and thereby indirectly acquire Community State Bank, Salem, Illinois.

D. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Cheyenne Banking Corporation*, Cheyenne, Oklahoma; to become a bank holding company by acquiring 100 percent of the voting shares of Security State Bank, Cheyenne, Oklahoma.

E. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *The ANB Corporation*, Terrell, Texas; to become a bank holding company by acquiring 100 percent of the voting shares of The ANB Delaware Corporation, Terrell, Texas, and thereby indirectly acquire The American National Bank of Terrell, Terrell, Texas. In connection with this application, The ANB Delaware Corporation, Terrell, Texas; also has applied to become a bank holding company by acquiring 100 percent of the voting shares of The American National Bank of Terrell, Terrell, Texas.

2. *Paladon Management Company, Inc.*, Panhandle, Texas; also has applied to become a bank holding company by acquiring 1 percent of the voting shares, and voting authority for 100 percent of Panhandle Investments, Ltd., Panhandle, Texas, and thereby

indirectly acquire Panhandle Bancshares, Inc., Panhandle, Texas, and First National Bank of Panhandle, Panhandle, Texas. In connection with this application, Paladon Investments, Ltd., Panhandle, Texas; to become a bank holding company by acquiring 41.29 percent of the voting shares of Panhandle Bancshares, Inc., Panhandle, Texas, and thereby indirectly acquire Panhandle National Bank of Panhandle, Panhandle, Texas, and First National Bank of Panhandle, Panhandle, Texas.

Board of Governors of the Federal Reserve System, December 7, 1994.

William W. Wiles,

Secretary of the Board.

[FR Doc. 94-30551 Filed 12-12-94; 8:45 am]

BILLING CODE 6210-01-F

Keystone Financial; Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies; Correction

This notice corrects a notice (FR Doc. 94-29458) published on page 61335 of the issue for Wednesday, November 30, 1994.

Under the Federal Reserve Bank of Philadelphia heading, the entry for Keystone Financial, Inc., is revised to read as follows:

1. *Keystone Financial, Inc.*, Harrisburg, Pennsylvania; to acquire Frankford Trust Company, Philadelphia, Pennsylvania, and thereby engage directly and indirectly in trust activities of the former Frankford Trust Company, Philadelphia, Pennsylvania, to be renamed Key Trust Company, pursuant to section 225.25(b)(3) of the Board's Regulation Y.

Comments on this application must be received by December 13, 1994.

Board of Governors of the Federal Reserve System, December 7, 1994.

William W. Wiles,

Secretary of the Board.

[FR Doc. 94-94-30552 Filed 12-12-94; 8:45 am]

BILLING CODE 6210-01-F

GENERAL SERVICES ADMINISTRATION

Performance Review Board; Membership; Senior Executive Service

AGENCY: General Services Administration.

ACTION: Notice.

SUMMARY: Notice is hereby given of the names of the members of the Performance Review Board.

FOR FURTHER INFORMATION CONTACT:

Gail T. Lovelace, Director of Personnel, General Services Administration, 18th & F Streets NW., Washington, DC 20405, (202) 501-0398.

SUPPLEMENTARY INFORMATION: Section 4313(c) (1) through (5) of Title 5 U.S.C. requires each agency to establish in accordance with regulations prescribed by the Office of Personnel Management, one or more Performance Review Board(s). The Board(s) shall review the performance rating of each senior executive's performance by the supervisor, along with any recommendations to the appointing authority relative to the performance of the senior executive.

Members of the Review Board are:

1. Julia M. Stasch, (Chairperson) Deputy Administrator
2. Karen R. Adler, Regional Administrator, Northeast and Caribbean Region (New York)
3. Paul E. Chistolini, Regional Administrator, Mid-Atlantic Region (Philadelphia)
4. Thurman M. Davis, Regional Administrator, National Capital Region (Washington, DC)
5. Dennis J. Fischer, Chief Financial Officer
6. Marlene M. Johnson, Associate Administrator for Management Services and Human Resources
7. Kenneth R. Kimbrough, Commissioner, Public Buildings Service
8. Frank P. Pugliese, Commissioner, Federal Supply Service
9. Joe M. Thompson, Commissioner, Information Technology Service

Dated: December 6, 1994.

Gail T. Lovelace,

Director of Personnel.

[FR Doc. 94-30564 Filed 12-12-94; 8:45 am]

BILLING CODE 6820-34-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Committee on Vital and Health Statistics (NCVHS) Subcommittee on State and Community Health Statistics: Meeting

Pursuant to Public Law 92-463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following meeting.

Name: NCVHS Subcommittee on State and Community Health Statistics.

Time and Date: 9 a.m.-5 p.m., January 19, 1995.

Place: Room 303A, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Washington, D.C. 20201.

Status: Open.

Purpose: The subcommittee will meet to discuss issues related to State and community statistics and to develop a work plan for the coming year.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436-7050.

Dated: December 1, 1994.

William H. Gimson,

Acting Associate Director for Policy Coordination, Center for Disease Control and Prevention (CDC).

[FR Doc. 94-30538 Filed 12-12-94; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

[Docket No. 94F-0152]

Roquette America, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Roquette America, Inc., has filed a petition proposing that the food additive regulations be amended to permit the manufacture of mannitol by fermentation of sugars or sugar alcohols such as glucose, sucrose, fructose, or sorbitol by the action of the yeast *Zygosaccharomyces rouxii*.

DATES: Written comments on the petitioner's environmental assessment by January 12, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857

FOR FURTHER INFORMATION CONTACT: Rosalie M. Angeles, Center for Food Safety and Applied Nutrition (HFS-207), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3107

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 4A4412) has been filed by Roquette America, Inc., c/o Keller and Heckman, 1001 G St. NW., Washington, DC 20001. The petition proposes that the food additive regulations in § 180.25 *Mannitol* (21 CFR 180.25) be amended

to permit the manufacture of mannitol by fermentation of sugars or sugar alcohols such as glucose, sucrose, fructose, or sorbitol by the action of the yeast *Zygosaccharomyces rouxii*.

As part of FDA's comprehensive safety review of substances on the list of substances generally recognized as safe (GRAS), the safety of mannitol as a food ingredient was evaluated in 1972 by the Select Committee on GRAS Substances (SCOGS) from the Life Sciences Research Office of the Federation of American Societies for Experimental Biology (FASEB). SCOGS concluded that mannitol was safe when used in food at current or reasonably expected future levels. In the *Federal Register* of July 26, 1973 (38 FR 20046), FDA proposed to affirm the GRAS status of mannitol that was manufactured by the process then known to the agency.

In response to the proposal, the agency received a comment stating that mannitol was also commonly manufactured by a process different from that set out in the proposed GRAS affirmation. The agency also received information raising questions about the safety of mannitol. Data from studies on mannitol demonstrated a significant (but not dose related) incidence of benign thymomas, and an abnormal growth of thymus gland tissue, in female rats fed mannitol.

As a result of these findings, the agency concluded that additional data were necessary to evaluate the safety of mannitol. Thus, in the *Federal Register* of September 23, 1974 (39 FR 34178), the agency declined to affirm the use of mannitol as GRAS and, instead, established an interim food additive regulation for use of mannitol at existing levels. The interim regulation, § 121.4005 (21 CFR 121.4005) (redesignated as § 180.25 (21 CFR 180.25)) required that mannitol be manufactured by either the process FDA had proposed to affirm as GRAS or the process described in the comment.

Following the publication of the interim food additive regulation, the agency received data that showed an increased combined incidence of medullary hyperplasia and pheochromocytoma of the adrenal glands in Fischer rats fed a diet of 10 percent mannitol. No such mannitol-treatment effect, however, was observed in Sprague-Dawley and Wistar rats.

In 1985, FASEB, under contract with FDA, established an ad hoc Expert Panel on Sugar Alcohols and Lactose to study certain effects that had been observed in animal experiments in which the test animals were fed sugar alcohols and lactose. In a report submitted to FDA in 1986, "Health Aspects of Sugar

Alcohols and Lactose," FASEB concluded that there was a statistically significant increased incidence of adrenal medullary hyperplasia and pheochromocytoma in rats fed high levels of sugar alcohols, including mannitol. The report further concluded that the existing data provided no satisfactory mechanistic explanations of these adrenal medullary lesions, which are commonly found in aged rats maintained on standard laboratory diets.

FDA is continuing to evaluate the FASEB report on sugar alcohols, including mannitol, as well as other data from animal studies of these substances to determine whether any regulatory action is appropriate for any or all of the sugar alcohols. During this period of continuing evaluation, mannitol continues to be listed, on an interim basis, for food use.

Roquette America's petition to amend the interim food additive regulation on mannitol, if granted, would not change the allowed uses of mannitol; it would simply permit a new method of manufacture of the additive. The subject regulation on mannitol specifies manufacturing procedures that do not include the fermentation process used in Roquette's production of mannitol. To permit a new manufacturing method, Roquette's petition proposes to amend the interim food additive regulation (§ 180.25) to provide for the use of *Zygosaccharomyces rouxii* in the fermentation process of producing mannitol from sugars and sugar alcohols.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before January 12, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review,

the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: November 28, 1994.

Alan M. Kulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 94-30585 Filed 12-12-94; 8:45 am]

BILLING CODE 4160-01-F

Health Resources and Services Administration

Program Announcement and Proposed Minimum Percentages for "High Rate" and "Significant Increase in the Rate" for Implementation of the General Statutory Funding Preference for Grants for Podiatric Primary Care Residency Training Programs

The Health Resources and Services Administration (HRSA) announces that applications will be accepted for fiscal year (FY) 1995 Grants for Podiatric Primary Care Residency Training Programs under the authority of section 751, title VII of the Public Health Service Act, as amended by the Health Professions Education Extension Amendments of 1992, Pub. L. 102-408, dated October 13, 1992. Comments are invited on the proposed minimum percentages for "high rate" and "significant increase in the rate" for the implementation of the general statutory funding preference.

Approximately \$600,000 will be available in FY 1995 for this program. It is anticipated that the \$600,000 will support approximately 7 competing awards averaging \$86,000.

Purpose

Section 751 authorizes the award of grants for the purpose of planning and implementing projects in primary care training for podiatric physicians in approved or provisionally approved residency programs which shall provide financial assistance in the form of traineeships to residents who participate in such projects and who plan to specialize in primary care.

Eligibility

Eligible entities for this program are schools of podiatric medicine and public and nonprofit private hospitals. As noted above, the authorizing legislation limits eligibility to residency

programs that are approved or provisionally approved. The Council on Podiatric Medical Education (CPME), the recognized accrediting body for podiatric medicine, uses the term "candidate status" in lieu of "provisional approval." For the purposes of this program "candidate status" will be accepted as meeting the statutory requirement for "provisional approval."

Applicants to this program that are planning to initiate a new podiatric primary care residency program are expected to apply to CPME for candidate status. Grants will only be awarded to applicants that can demonstrate the attainment of candidate status by July 1, 1995. The application for Federal funding must demonstrate, through responses to the program specifications, that an adequate emphasis will be placed on podiatric primary care.

The period of Federal support should not exceed 3 years.

National Health Objectives for the Year 2000

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. The Podiatric Primary Care Residency Training Program is related to the priority area of Educational and Community-Based Programs. Potential applicants may obtain a copy of Healthy People 2000 (Full Report; Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report; Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402-9325 (Telephone 202-783-3238).

Education and Service Linkage

As part of its long-range planning, HRSA will be targeting its efforts to strengthening linkages between U.S. Public Health Service education programs and programs which provide comprehensive primary care services to the underserved.

Smoke-Free Workplace

The Public Health Service strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.

The following project requirements and review criteria were established in FY 1989, after public comment and are